Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug 27:10:2045125320937575.
doi: 10.1177/2045125320937575. eCollection 2020.

Dopamine-receptor blocking agent-associated akathisia: a summary of current understanding and proposal for a rational approach to treatment

Shaina Musco  1 , Vivian McAllister  2 , Ian Caudle  3
Affiliations
Review

Dopamine-receptor blocking agent-associated akathisia: a summary of current understanding and proposal for a rational approach to treatment

Shaina Musco et al. Ther Adv Psychopharmacol. .

Abstract

Dopamine-receptor blocking agent-associated akathisia (DRBA-A) is an adverse effect that can significantly limit the use of these important medications for the treatment of a variety of psychiatric diseases, yet there is no unifying theory regarding its pathophysiology. This knowledge gap limits clinicians' ability to effectively manage DRBA-A and mitigate negative outcomes in an already vulnerable patient population. Based on a review of the current literature on the subject, it is hypothesized that dopaminergic and noradrenergic signaling is perturbed in DRBA-A. Accordingly, it is proposed that the optimal agent to manage this extrapyramidal symptom should increase dopamine signaling in the affected areas of the brain and counteract compensatory noradrenergic signaling via antagonism of adrenergic or serotonergic receptors.

Keywords: akathisia; antipsychotic; dopamine receptor blocking agent; extrapyramidal symptom; mechanism; treatment.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare that there is no conflict of interest.

Figures

Figure 1.
Figure 1.
Proposed neural circuitry underlying second generation DRBA-A. 5-HT2A, serotonin receptor subtype; Ach, acetylcholine; D2, dopamine receptor subtype; DRBA, dopamine receptor blocking agent; DRBA-A, dopamine-receptor blocking agent-associated akathisia; GABA, gamma-aminobutyric acid; NE, norepinephrine. Stimulatory pathways end with an arrow (▼) and inhibitory pathways end with a line (▬).
See this image and copyright information in PMC

References

    1. Belmaker RH, Wald D. Haloperidol in normals. Br J Psychiatry 1977; 131: 222–223. - PubMed
    1. Lohr JB, Eidt CA, Abdulrazzaq Alfaraj A, et al. The clinical challenges of akathisia. CNS Spectr 2015; 20(Suppl. 1): 1–14; quiz 5–6. - PubMed
    1. Kim JH, Byun HJ. Association of subjective cognitive dysfunction with akathisia in patients receiving stable doses of risperidone or haloperidol. J Clin Pharm Ther 2007; 32: 461–467. - PubMed
    1. Sachdev PS, Brune M. Animal models of acute drug-induced akathisia - a review. Neurosci Biobehav Rev 2000; 24: 269–277. - PubMed
    1. Kane JM, Fleischhacker WW, Hansen L, et al. Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry 2009; 70: 627–643. - PubMed

LinkOut - more resources